LPAR1 and rheumatoid arthritis: Subsequently, two independent groups demonstrated that inhibition of LPAR1 with Ki16425 or inhibition of the ATX-LPAR axis with the ATX-LPAR pan-antagonist Br-LPA reduced the clinical severities of collagen-induced arthritis or RA [72,73].